Terns Pharmaceuticals

Develops a pill to treat leukemia, a type of blood cancer.

Company Health

We couldn’t find yearly financial reports from this company with the SEC.

Who owns it

None of the 23 funds we follow reported owning Terns Pharmaceuticals in their latest reports. Melqart sold all their shares in their latest report.

bought lately

owns it

doesn’t own it

Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Greenlight, Giverny Capital, Fundsmith, Semper Augustus, Akre

Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners

From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works